



GLENN HEGAR TEXAS COMPTROLLER OF PUBLIC ACCOUNTS

MEMORANDUM

April 7, 2025

TO: Opioid Abatement Fund Council Members

FROM: Katy Fallon Brown, Director of Texas Opioid Abatement Fund Council

RE: **Revenue and Expenditures from Settlement Agreements/Court Orders**

This memorandum reflects funds received and available from settlement agreements or court orders as of April 7, 2025, totaling \$604,105,337.81, net attorney fees. This amount includes the \$126,406,089.48 allocated to the state legislature, the \$60,000,000 that the Council previously obligated for statewide grants in 2024 (excluding Naloxone grant reimbursements of \$26,368.10), and the \$100,000,000 in the Council's 2025 Grant Issuance Plan.

State Share		
Date	Description	Amount
January 2022	McKinsey	\$4,540,343.02
March 2022	J&J/Jansen	\$39,492,329.75
April 2022	McKinsey	\$197,362.26
June 2022	Endo	\$8,373,408.75
June 2022	Teva	\$4,730,437.50
January 2023	Global	\$11,820,474.74
May 2023	McKinsey	\$246,702.83
June 2023	Mallinckrodt	\$1,444,293.01
August 2023	Teva	\$750,000.00
November 2023	Global	\$7,633,192.47
November 2023	Mallinckrodt	\$1,699,168.24
February 2024	Walmart	\$8,996,224.64
April 2024	Global	\$4,218,578.02

State Share		
Date	Description	Amount
April 2024	Publicis	\$3,125,359.49
August 2024	Global	\$9,570,280.87
September 2024	Walgreens	\$4,257,067.66
September 2024	Walmart	\$9,620,595.28
September 2024	CVS	\$1,681,994.71
October 2024	Allergan	\$3,613,260.18
February 2025	Walmart	\$392,966.77
FY 2025 to date	Interest	\$2,049.29
Total		\$126,406,089.48

Trust Fund Share		
Date	Description	Amount
June 2022	Endo	\$38,575,907.50
June 2022	Teva	\$22,075,375.00
FY 2022	Interest	\$108,831.01
October 2022	J&J/Jansen	\$164,004,732.50
November 2022	Texas Access to Justice Foundation	(\$5,000,000.00)
January 2023	Global	\$25,325,280.96
June 2023	Mallinckrodt	\$6,740,034.03
August 2023	Teva	\$3,500,000.00
FY 2023	Interest	\$8,013,996.10
September 2023	McKinsey	\$22,819,947.11
October 2023	CPA Administrative Allocation	(\$493,000.00)
November 2023	Global	\$21,222,124.39
November 2023	Mallinckrodt	\$7,929,451.81
February 2024	Walmart	\$41,982,381.67

Trust Fund Share		
Date	Description	Amount
April 2024	Global	\$19,686,697.44
April 2024	Publicis	\$14,585,010.94
August 2024	CPA Administrative Allocation	\$493,000.00
August 2024	Global	\$30,198,894.76
August 2024	Hospital District Allocation	(\$65,770,854.13)
FY 2024	Interest	\$16,703,695.77
September 2024	Walmart	\$44,896,111.26
September 2024	CVS	\$7,849,308.62
September 2024	Walgreens	\$19,866,315.75
October 2024	Allergan	\$16,861,880.87
February 2025	Walmart	\$1,833,844.96
February 2025	Naloxone Grant Distribution	(\$26,368.10)
FY 2025 to date	Interest	\$12,166,689.47
Total		\$476,149,289.69

Subdivision Share		
Date	Description	Amount
June 2022	Endo	\$7,873,408.75
June 2022	Teva	\$4,730,437.50
FY 2022	Interest	\$7,069.86
October 2022	J&J/Jansen	\$30,166,610.48
January 2023	Global	\$3,940,050.62
August 2023	Teva	\$750,000.00
March 2023	Distribution	(\$47,088,165.36)
June 2023	Mallinckrodt	\$1,444,293.01

Subdivision Share		
Date	Description	Amount
FY 2023	Interest	\$677,775.48
September 2023	McKinsey	\$4,027,049.49
November 2023	Global	\$3,938,138.54
November 2023	Mallinckrodt	\$1,699,168.24
February 2024	Walmart	\$8,996,224.64
April 2024	Global	\$4,218,578.02
April 2024	Publicis	\$3,125,359.49
April 2024	Distribution	(\$9,160,657.93)
August 2024	Global	\$4,207,105.37
FY 2024	Interest	\$679,608.61
September 2024	Walmart	\$9,620,595.28
September 2024	CVS	\$1,681,994.71
September 2024	Walgreens	\$4,257,067.66
October 2024	Allergan	\$3,613,260.18
February 2025	Walmart	\$392,966.77
FY 2025 to date	Interest	\$1,044,527.37
March 2025	Distribution	(\$44,690,490.84)
Total		\$151,975.94

Unappropriated General Revenue		
Date	Description	Amount
April 2021	McKinsey	\$1,397,982.70
Total		\$1,397,982.70